Iridex Corp Sample Contracts

Iridex Corp – SEPARATION AGREEMENT AND GENERAL RELEASE (June 26th, 2019)

This Separation Agreement and General Release (hereinafter referred to as “Agreement”) is made and entered into by and between William M. Moore (hereinafter referred to as “Executive”) and Iridex Corporation (hereinafter referred to as “Iridex” or “Company”).

Iridex Corp – AMENDED AND RESTATED BYLAWS OF IRIDEX CORPORATION (April 1st, 2019)

An annual meeting of stockholders shall be held for the election of directors at such date, time and place (if any), within or without the state of Delaware, as may be designated by resolution of the Board of Directors from time to time and stated in the corporation’s notice of annual meeting. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead by held solely by means of remote communication as authorized by Section 211(a)(2) of the Delaware General Corporation Law (the “DGCL”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the corporation’s principal executive office. At the annual meeting, directors shall be elected and any other proper business brought in accordance with Section 1.4 of these bylaws may be transacted. The Board of Directors may cancel, postpone or reschedule any previously scheduled annual meeting at any time, before or after the

Iridex Corp – Mountain View, Calif., February 12, 2019— IRIDEX Corporation (Nasdaq: IRIX) today announced that it has resolved its differences with Quantel Medical, S.A., Quantel USA, Inc., and Quantel, S.A. (collectively, “Quantel”) in its lawsuit filed against Quantel in the U.S. District Court for the Northern District of California. IRIDEX dismissed the lawsuit it had filed in January 2018, alleging that Quantel products infringed IRIDEX’s U.S. Patent No. 7,771,417, that Quantel breached an earlier agreement between the parties, and that Quantel infringed IRIDEX’s MicroPulse® U.S. Trademark, Registratio (February 12th, 2019)

Quantel dismissed its lawsuit in Europe including Tribunal de grande instance de Paris, 3e chambre, 1e section, RG n° 18/06053, related to European patent n° 1 856 774 against IRIDEX and withdrew from participation in the Opposition to IRIDEX’s European Patent No. 1856774. IRIDEX filed a Notice of Appeal with the European Patent Office (EPO) in that proceeding in October 2018.

Iridex Corp – 1,666,667 Shares IRIDEX CORPORATION Common Stock UNDERWRITING AGREEMENT (September 18th, 2018)

IRIDEX Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate of 1,666,667 shares (the “Firm Shares”) of the common stock, par value $0.01 per share, of the Company (“Common Stock”). The Company also proposes to sell to the several Underwriters, at the option of the Underwriters, exercisable for 30 days from the date of the Prospectus (as defined below), up to an additional 250,000 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares”.

Iridex Corp – NEWS RELEASE (September 18th, 2018)

Mountain View, California, September 14, 2018 — IRIDEX Corporation (NASDAQ:IRIX) (“ IRIDEX “ or the “Company”), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, today announced the pricing of its underwritten public offering of 1,666,667 shares of its common stock at a price to the public of $6.00 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 250,000 additional shares of its common stock in the public offering.

Iridex Corp – NEWS RELEASE (September 18th, 2018)

Mountain View, California, September 13, 2018 — IRIDEX Corporation (NASDAQ:IRIX) (“IRIDEX” or the “Company”), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. IRIDEX also expects to grant the underwriters for the offering a 30-day option to purchase an additional 15% of the shares of its common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by IRIDEX.

Iridex Corp – IRIDEX CORPORATION CHANGE IN CONTROL SEVERANCE AGREEMENT (December 11th, 2017)

This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between George Marcellino (“Executive”) and IRIDEX Corporation, a Delaware corporation (the “Company”), effective as of December 6, 2017 (the “Effective Date”).

Iridex Corp – I am very pleased to extend to you this employment offer for the full‑time position of (October 5th, 2017)
Iridex Corp – PARTIES (May 1st, 2017)

This Lease is executed in duplicate in Mountain View, California, this 26th day of April, 2017, by and between ZIC 1212 Terra Bella LLC, a California limited liability company, and Iridex Corporation, a Delaware corporation, hereinafter referred to respectively as “Lessor” and “Lessee”, without regard to number or gender.

Iridex Corp – IRIDEX CORPORATION UNDERWRITING AGREEMENT 1,150,000 Shares of Common Stock (December 14th, 2016)

IRIDEX Corporation, a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to Roth Capital Partners, LLC (the “Underwriter”) an aggregate of 1,150,000 authorized but unissued shares (the “Firm Shares”) of common stock, par value $0.01 per share (the “Common Stock”), of the Company. The Company also proposes to sell to the Underwriter, upon the terms and conditions set forth in Section 4 hereof, up to an additional 172,500 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares.”

Iridex Corp – LOAN AND SECURITY AGREEMENT (November 3rd, 2016)

THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of November 2, 2016 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and IRIDEX CORPORATION, a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:

Iridex Corp – IRIDEX CORPORATION TO AS TRUSTEE INDENTURE DATED AS OF , 20 SENIOR DEBT SECURITIES (August 12th, 2016)

INDENTURE, dated as of , 20 , between IRIDEX Corporation, a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), having its principal executive office at 1212 Terra Bella Avenue, Mountain View, California 94043, and , as Trustee (herein called the “Trustee”).

Iridex Corp – IRIDEX CORPORATION TO AS TRUSTEE INDENTURE DATED AS OF , 20 SUBORDINATED DEBT SECURITIES (August 12th, 2016)

INDENTURE, dated as of , 20 , between IRIDEX Corporation, a corporation duly organized and existing under the laws of the State of Delaware (herein called the “Company”), having its principal executive office at 1212 Terra Bella Avenue, Mountain View, California 94043, and , as Trustee (herein called the “Trustee”).

Iridex Corp – IRIDEX CORPORATION INDEMNIFICATION AGREEMENT (July 11th, 2016)

This Indemnification Agreement ("Agreement") is entered into effective as of the ___ day of _______________, 2016, by and between IRIDEX Corporation, a Delaware corporation (the "Company") and ____________________ ("Indemnitee").

Iridex Corp – IRIDEX CORPORATION CHANGE IN CONTROL SEVERANCE AGREEMENT (July 11th, 2016)

This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Atabak Mokari (“Executive”) and IRIDEX Corporation, a Delaware corporation (the “Company”), effective as of July 11, 2016 (the “Effective Date”).

Iridex Corp – CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS (June 21st, 2016)

This Confidential Separation Agreement and Release of All Claims (hereinafter referred to as the “Separation Agreement”) is entered into by IRIDEX Corporation (hereafter “Iridex”) and Ronald Steckel (hereafter “Steckel”) (collectively, the “Parties”) to arrange for the separation of Steckel with Iridex on a basis that is satisfactory to the Parties.

Iridex Corp – FOURTH AMENDMENT TO LEASE (March 31st, 2016)

THIS FOURTH AMENDMENT TO LEASE (this “Amendment”) is dated as of January 31, 2016, and is entered into by and between Zappettini Investment Company, a California general partnership (“Lessor”), and IRIDEX Corporation (“Lessee”).

Iridex Corp – STOCK OPTION CANCELLATION AGREEMENT (September 8th, 2015)

THIS STOCK OPTION CANCELLATION AGREEMENT (this “Agreement”) is entered into as of September 2, 2015, by and among Iridex Corporation, a Delaware corporation (“Iridex”), and James H. Mackaness (the “Optionee”).

Iridex Corp – IRIDEX CORPORATION AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE AGREEMENT (May 12th, 2015)

This Amended and Restated Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between James H. Mackaness (“Executive”) and IRIDEX Corporation, a Delaware corporation (the “Company”), effective as of March 30, 2015 (the “Effective Date”).

Iridex Corp – IRIDEX CORPORATION CHANGE IN CONTROL SEVERANCE AGREEMENT (May 12th, 2015)

This Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between William M. Moore (“Executive”) and IRIDEX Corporation, a Delaware corporation (the “Company”), effective as of March 30, 2015 (the “Effective Date”).

Iridex Corp – IRIDEX CORPORATION AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE AGREEMENT (May 12th, 2015)

This Amended and Restated Change in Control Severance Agreement (the “Agreement”) is made and entered into by and between Ronald T. Steckel (“Executive”) and IRIDEX Corporation, a Delaware corporation (the “Company”), effective as of March 30, 2015 (the “Effective Date”).

Iridex Corp – THIRD AMENDMENT TO LEASE (November 3rd, 2014)

THIS THIRD AMENDMENT TO LEASE (this “Amendment”) is dated as of August 4, 2014, and is entered into by and between Zappettini Investment Company, a California general partnership (“Lessor”), and Iridex Corporation (“Lessee”).

Iridex Corp – 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (January 9th, 2014)

Unless otherwise defined herein, the terms defined in the IRIDEX Corporation (the “Company”) 2008 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement (the “Award Agreement”).

Iridex Corp – IRIDEX CORPORATION ADEA WAIVER AGREEMENT AND RELEASE (March 28th, 2013)

This ADEA Waiver Agreement and Release (the “ADEA Waiver” or the “Agreement”) is made by and between Dr. Dominik Beck (“Employee”) and IRIDEX Corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”).

Iridex Corp – IRIDEX CORPORATION AGREEMENT AND RELEASE (March 28th, 2013)

This Separation Agreement and Release (“Agreement”) is made by and between Dr. Dominik Beck (“Employee”) and IRIDEX Corporation (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”) effective on the Effective Date (defined below).

Iridex Corp – IRIDEX CORPORATION 2008 EQUITY INCENTIVE PLAN (as amended April 26, 2012) (March 28th, 2013)
Iridex Corp – IRIDEX CORPORATION 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (March 27th, 2013)

Unless otherwise defined herein, the terms defined in the IRIDEX Corporation (the “Company”) 2008 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement (the “Award Agreement”).

Iridex Corp – IRIDEX Corporation Executive Management Bonus Plan Summary (February 21st, 2012)

PURPOSE The purpose of the Plan is to provide an incentive for the achievement of Goals that support IRIDEX Strategic Plan.

Iridex Corp – ASSET PURCHASE AGREEMENT by and between CUTERA, INC., a Delaware corporation, IRIDEX CORPORATION, a Delaware corporation, and as Escrow Agent Dated as of December 30, 2011 (January 4th, 2012)

This ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of December 30, 2011 by and between, Cutera, Inc., a Delaware corporation (“Buyer”), IRIDEX Corporation, a Delaware corporation (the “Company”) and with respect to Article 7 hereof only, U.S. Bank National Association (the “Escrow Agent”).

Iridex Corp – EXECUTIVE TRANSITION AGREEMENT (October 12th, 2011)

This Executive Transition Agreement (the “Agreement”) is made and entered into by and between Theodore A. Boutacoff (“Employee”) and Iridex Corporation (the “Company”), effective as of October 10, 2011 (the “Effective Date”).

Iridex Corp – Press Release IRIDEX Names Veteran Healthcare Executive Dominik Beck President, CEO Theodore A. Boutacoff Named CTO to Lead Effort to Commercialize Innovative MicroPulse Technology (October 12th, 2011)

MOUNTAIN VIEW, Calif., Oct. 10, 2011 /PRNewswire via COMTEX/ — IRIDEX Corporation (Nasdaq: IRIX) (the “Company”) today announced that Dominik Beck has been named President and Chief Executive Officer effective today. Dr. Beck replaces Theodore A. Boutacoff, a co-founder of IRIDEX who will become Chief Technology Officer, and will also replace Mr. Boutacoff on the IRIDEX Board of Directors.

Iridex Corp – IRIDEX CORPORATION EMPLOYMENT AGREEMENT (October 12th, 2011)

This Employment Agreement (the “Agreement”) is entered into as of August 16, 2011 by and between Iridex Corporation (the “Company”), and Dr. Dominik Beck (“Executive”).

Iridex Corp – IRIDEX CORPORATION 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT (August 4th, 2011)

Unless otherwise defined herein, the terms defined in the IRIDEX Corporation 2008 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Award Agreement (the “Award Agreement”).

Iridex Corp – IRIDEX CORPORATION 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT (August 4th, 2011)

Unless otherwise defined herein, the terms defined in the IRIDEX Corporation (the “Company”) 2008 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Award Agreement (the “Award Agreement”).

Iridex Corp – IRIDEX Corporation 2011 Senior Staff Bonus Plan Summary (March 10th, 2011)

To provide cash incentive bonus payouts to eligible employees based upon Company and individual performance in exceeding Revenue performance and Operating Income performance to Plan.